C4 Therapeutics Stock Forecast, Price & News

+1.66 (+3.85 %)
(As of 08/2/2021 11:40 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,849 shs
Average Volume360,364 shs
Market Capitalization$1.94 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CCCC News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

C4 Therapeutics logo

About C4 Therapeutics

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.


C4 Therapeutics Inc.
C4 Therapeutics Inc.
August 1, 2021 |
C4 Therapeutics Stock Enters Leadership Territory
C4 Therapeutics Stock Enters Leadership Territory
July 19, 2021 |
C4 Therapeutics (NASDAQ:CCCC) Trading 5.8% Higher
C4 Therapeutics (NASDAQ:CCCC) Trading 5.8% Higher
July 16, 2021 |
C4 Therapeutics (NASDAQ:CCCC) Stock Price Down 2.3%
C4 Therapeutics (NASDAQ:CCCC) Stock Price Down 2.3%
July 9, 2021 |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)
June 26, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.96 out of 5 stars

Medical Sector

640th out of 2,221 stocks

Biological Products, Except Diagnostic Industry

91st out of 214 stocks

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

C4 Therapeutics (NASDAQ:CCCC) Frequently Asked Questions

Is C4 Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" C4 Therapeutics stock.
View analyst ratings for C4 Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than C4 Therapeutics?

Wall Street analysts have given C4 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but C4 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is C4 Therapeutics' next earnings date?

C4 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for C4 Therapeutics

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its earnings results on Thursday, May, 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.14. The business earned $7.43 million during the quarter.
View C4 Therapeutics' earnings history

What price target have analysts set for CCCC?

6 equities research analysts have issued twelve-month target prices for C4 Therapeutics' stock. Their forecasts range from $34.00 to $63.00. On average, they anticipate C4 Therapeutics' stock price to reach $51.50 in the next year. This suggests a possible upside of 15.0% from the stock's current price.
View analysts' price targets for C4 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are C4 Therapeutics' key executives?

C4 Therapeutics' management team includes the following people:
  • Mr. Marc A. Cohen, Co-Founder, Exec. Chairman & Sec. (Age 58, Pay $69.5k)
  • Mr. Andrew J. Hirsch, CEO, Pres & Director (Age 50, Pay $607.96k)
  • Dr. Kenneth C. Anderson Ph.D., M.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 70, Pay $27.5k)
  • Mr. William T. McKee, Interim CFO & Treasurer (Age 59, Pay $1.07M)
  • Dr. Adam S. Crystal M.D., Ph.D., Chief Medical Officer (Age 44, Pay $661.55k)
  • Dr. Nathanael S. Gray Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Stewart Fisher, Chief Scientific Officer (Age 54)
  • Ms. Kendra Adams, Sr. VP of Communications & Investor Relations
  • Ms. Jolie M. Siegel J.D., Chief Legal Officer (Age 44)
  • Kristina Zambouras, Director of HR

Who are some of C4 Therapeutics' key competitors?

When did C4 Therapeutics IPO?

(CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

What is C4 Therapeutics' stock symbol?

C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."

Who are C4 Therapeutics' major shareholders?

C4 Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.14%) and Eagle Health Investments LP (0.11%). Company insiders that own C4 Therapeutics stock include Adam Crystal, Malcolm Salter, Marc A Cohen and William Mckee.
View institutional ownership trends for C4 Therapeutics

Which major investors are buying C4 Therapeutics stock?

CCCC stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and Eagle Health Investments LP. Company insiders that have bought C4 Therapeutics stock in the last two years include Marc A Cohen, and William Mckee.
View insider buying and selling activity for C4 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of C4 Therapeutics?

Shares of CCCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is C4 Therapeutics' stock price today?

One share of CCCC stock can currently be purchased for approximately $44.80.

How much money does C4 Therapeutics make?

C4 Therapeutics has a market capitalization of $1.94 billion and generates $33.19 million in revenue each year. The company earns $-66,330,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.

How many employees does C4 Therapeutics have?

C4 Therapeutics employs 99 workers across the globe.

What is C4 Therapeutics' official website?

The official website for C4 Therapeutics is

How can I contact C4 Therapeutics?

The company can be reached via phone at 617 231 0700 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.